LON:EDEN Eden Research (EDEN) Share Price, News & Analysis GBX 3.50 +0.10 (+2.82%) As of 06:37 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesBuy This Stock About Eden Research Stock (LON:EDEN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Eden Research alerts:Sign Up Key Stats Today's Range 3.26▼ 3.5050-Day Range 3.26▼ 4.1952-Week Range 2.23▼ 4.67Volume150,500 shsAverage Volume542,917 shsMarket Capitalization£18.65 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Eden Research is the only UK-listed company focused on biopesticides for sustainable agriculture. It develops and supplies innovative biopesticide products and natural microencapsulation technologies to the global crop protection, animal health and consumer products industries. Eden's products are formulated with terpene active ingredients, based on natural plant defence metabolites. To date, they have been primarily used on high-value fruits and vegetables, improving crop yields and marketability, with equal or better performance when compared with conventional pesticides. Eden has two products currently on the market: Based on plant-derived active ingredients, Mevalone ® is a foliar biofungicide which initially targets a key disease affecting grapes and other high-value fruit and vegetable crops. It is a useful tool in crop defence programmes and is aligned with the requirements of integrated pest management programmes. It is approved for sale in a number of key countries whilst Eden and its partners pursue regulatory clearance in new territories thereby growing Eden's addressable market globally. Cedroz ™ is a bionematicide that targets free living nematodes which are parasitic worms that affect a wide range of high-value fruit and vegetable crops globally. Cedroz is registered for sale on two continents and Eden's commercial collaborator, Eastman Chemical, is pursuing registration and commercialisation of this important new product in numerous countries globally. Eden's Sustaine ® encapsulation technology is used to harness the biocidal efficacy of naturally occurring chemicals produced by plants (terpenes) and can also be used with both natural and synthetic compounds to enhance their performance and ease-of-use. Sustaine microcapsules are naturally-derived, plastic-free, biodegradable micro-spheres derived from yeast. It is one of the only viable, proven and immediately registerable solutions to the microplastics problem in formulations requiring encapsulation. Eden was admitted to trading on AIM on 11 May 2012 and trades under the symbol EDEN. It was awarded the London Stock Exchange Green Economy Mark in January 2021, which recognises London-listed companies that derive over 50% of their total annual revenue from products and services that contribute to the global green economy. Eden derives 100% of its total annual revenues from sustainable products and services. For more information about Eden, please visit: www.edenresearch.com . Read More Receive EDEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Eden Research and its competitors with MarketBeat's FREE daily newsletter. Email Address EDEN Stock News HeadlinesHere’s why Texas is one of the most dangerous states to raise a family in 2025July 16, 2025 | msn.comYgia acquires Eden to become Cyprus’ largest private hospital groupJuly 15, 2025 | msn.comI warned you about Nvidia… now look what’s happeningNvidia just got Trump’s greenlight to sell high-powered AI chips to China — and their stock surged 5% before the open. That’s the kind of move Tim Sykes built his XGPT system to trade. It scans AI news in real time, filters the noise, and pinpoints when to strike. He’s now showing exactly how it works — before the next headline hits.July 25 at 2:00 AM | Timothy Sykes (Ad)Eden Research partners with Royal Holloway on seed treatment productJune 16, 2025 | lse.co.ukEden Expands Metabolic Health Access Services with NAD⁺ via Injections, Patch, and Nasal-Spray FormatsMay 29, 2025 | finance.yahoo.comEden Appoints Dr. Halland Chen, MD as Chief Medical Innovation OfficerMay 29, 2025 | finance.yahoo.comBest Shoes at Cannes amfAR Gala 2025 Red Carpet [PHOTOS]May 23, 2025 | yahoo.comCelebrities unite at exclusive Cannes gala to support AIDS research after Trump cutsMay 23, 2025 | msn.comSee More Headlines EDEN Stock Analysis - Frequently Asked Questions How have EDEN shares performed this year? Eden Research's stock was trading at GBX 3.90 at the beginning of 2025. Since then, EDEN shares have decreased by 10.3% and is now trading at GBX 3.50. How were Eden Research's earnings last quarter? Eden Research plc (LON:EDEN) posted its quarterly earnings results on Tuesday, May, 6th. The company reported ($0.36) EPS for the quarter. Eden Research had a negative trailing twelve-month return on equity of 11.63% and a negative net margin of 38.70%. How do I buy shares of Eden Research? Shares of EDEN stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of Eden Research own? Based on aggregate information from My MarketBeat watchlists, some other companies that Eden Research investors own include Kromek Group (KMK), Primary Health Properties (PHP), National Grid (NG.L), Cabot Energy (CAB), EPE Special Opportunities (ESO), Marston's (MARS) and Mothercare (MTC). Company Calendar Last Earnings5/06/2025Today7/25/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorBasic Materials Industry Agricultural Inputs Sub-IndustryN/A Current SymbolLON:EDEN CIKN/A Webwww.edenresearch.com Phone+44-1285-359555FaxN/AEmployees19Year FoundedN/AProfitability EPS (Trailing Twelve Months)GBX (0.29) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-£1.52 million Net Margins-38.70% Pretax MarginN/A Return on Equity-11.63% Return on Assets-11.29% Debt Debt-to-Equity Ratio1.26 Current Ratio3.80 Quick Ratio2.42 Sales & Book Value Annual Sales£3.93 million Price / Sales4.74 Cash FlowGBX 0.29 per share Price / Cash Flow11.90 Book ValueGBX 2.38 per share Price / Book1.47Miscellaneous Outstanding Shares533,353,000Free FloatN/AMarket Cap£18.65 million OptionableNot Optionable Beta0.92 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (LON:EDEN) was last updated on 7/25/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eden Research plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Eden Research With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.